✦ LIBER ✦

Reply to Genetic polymorphisms of CYP2D610 and CYP2C192,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Scribed by Shinzaburo Noguchi; Masatsugu Okishiro

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 53 KB
Volume: 116
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24830

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Masatsugu Okishiro; Tetsuya Taguchi; Seung Jin Kim; Kenzo Shimazu; Yasuhiro Tama 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 469 KB

Reply to Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

Reply to Genetic polymorphisms of CYP2D610 and CYP2C192,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen